Skip to main content
. Author manuscript; available in PMC: 2018 Jan 10.
Published in final edited form as: Circulation. 2017 Jan 10;135(2):180–195. doi: 10.1161/CIRCULATIONAHA.116.022622

Figure 2. Estimated Lifetime Absolute Benefits of Intensive Glycemic Control for Preventing Microvascular Outcomes.

Figure 2

A. Treatment Scenario 1: initiation of metformin at diagnosis, with HbA1c reduction from 8.5% to 7.0%

B. Treatment Scenario 2: initiation of insulin 10 years after ‘failing’ initial oral therapy, with HbA1c reduction from 8.5% to 7.5%

Abbreviations: ESRD, end-stage renal disease; MI, myocardial infarction. The number needed to treat values were calculated from the estimated absolute risk reductions based on Vijan and colleagues’ Markov simulation model.40 For scenario 2, the absolute risk reduction for prevention vision loss among 75 year olds with new-onset diabetes was 0%, thus yielding a number needed to treat of infinity.